The use of antibody modified liposomes loaded with AMO-1 to deliver oligonucleotides to ischemic myocardium for arrhythmia therapy

Biomaterials

Volumn 35, Issue 11, 2014, Pages 3697-3707

  Liu, Meifang ^a   Li, Minghui ^a   Sun, Shouli ^a   Li, Baoxin ^b   Du, Dan ^a   Sun, Jialiang ^b   Cao, Fangyuan ^a   Li, Haichun ^a   Jia, Feng ^c   Wang, Tianfu ^c   Chang, Naidan ^a   Yu, Hui ^a   Wang, Qun ^c,d   Peng, Haisheng ^a,c  

^a Daqing Campus of Harbin Medical University ^*  (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c IOWA STATE UNIVERSITY   (United States)

^d Iowa State University   (United States)

Author keywords

Anti cTnI antibody; Antisense oligonucleotide; In vivo imaging; Ischemic arrhythmias; Liposomes; MicroRNA 1

Indexed keywords

ANTI-CTNI ANTIBODY; ANTISENSE OLIGONUCLEOTIDE; IN VIVO IMAGING; ISCHEMIC ARRHYTHMIAS; LIPOSOMES; MICRORNA-1;

ANIMALS; ANTIBODIES; ARRHYTHMIAS, CARDIAC; CELL SURVIVAL; FLOW CYTOMETRY; LIPOSOMES; MICRORNAS; MYOCARDIAL ISCHEMIA; MYOCARDIUM; OLIGONUCLEOTIDES, ANTISENSE; PARTICLE SIZE; RATS; RATS, WISTAR; STATIC ELECTRICITY; TIME FACTORS; TIME-LAPSE IMAGING; TROPONIN I;

EID: 84894985306     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.12.099     Document Type: Article

References (44)

1. Kim M.C., Kini A., Sharma S.K. Refractory angina pectoris: mechanism and therapeutic options. J Am Coll Cardiol 2002, 39:923-934.
2. Yang B., Lin H., Xiao J., Lu Y., Luo X., Li B., et al. The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. J Nat Med 2007, 13:486-491.
3. Krutzfeldt J., Rajewsky N., Braich R., Rajeev K.G., Tuschl T., Manoharan M., et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005, 438:685-689.
4. Cheng A.M., Byrom M.W., Shelton J., Ford L.P. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res 2005, 33:1290-1297.
5. Grines C.L., Watkins M.W., Helmer G., Penny W., Brinker J., Marmur J.D., et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002, 105:1291-1297.
6. Huang M., Chan D.A., Jia F., Xie X., Li Z., Hoyt G., et al. Short hairpin RNA interference therapy for ischemic heart disease. Circulation 2008, 118:S226-S233.
7. Nabel E.G. Gene therapy for cardiovascular disease. Circulation 1995, 91:541-548.
8. Natarajan R., Salloum F.N., Fisher B.J., Kukreja R.C., Fowler A.A. Hypoxia inducible factor-1 activation by prolyl 4-hydroxylase-2 gene silencing attenuates myocardial ischemia reperfusion injury. Circ Res 2006, 98:133-140.
9. Chen X., Wang X., Wang Y., Yang L., Hu J., Xiao W., et al. Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide. J Control Release 2010, 145:17-25.
10. Ylä-Herttuala S., Alitalo K. Gene transfer as a tool to induce therapeutic vascular growth. J Nat Med 2003, 9:694-701.
11. Lu Y., Xiao J., Lin H., Bai Y., Luo X., Wang Z., et al. A single anti-microRNA antisense oligodeoxyribonucleotide (AMO) targeting multiple microRNAs offers an improved approach for microRNA interference. Nucleic Acids Res 2009, 37:e24.
12. Gao Y., Liu X.L., Li X.R. Research progress on siRNA delivery with nonviral carriers. Int J Nanomedicine 2011, 6:1017-1025.
13. Whitehead K.A., Langer R., Anderson D.G. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009, 8:129-138.
14. Zangi L., Lui K.O., von Gise A., Ma Q., Ebina W., Ptaszek L.M., et al. Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Nat Biotechnol 2013, 31:898-907.
15. Chen J.F., Mandel E.M., Thomson J.M., Wu Q., Callis T.E., Hammond S.M., et al. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet 2006, 38:228-233.
16. McCarthy J.J., Esser K.A. MicroRNA-1 and microRNA-133a expression are decreased during skeletal muscle hypertrophy. J Appl Physiol (1985) 2007, 102:306-313.
17. Gardlik R., Celec P., Bernadic M. Targeting angiogenesis for cancer (gene) therapy. Bratisl Lek Listy 2011, 112:428-434.
18. Liu C.C., Shen Z., Kung H.F., Lin M.C. Cancer gene therapy targeting angiogenesis: an updated review. World J Gastroenterol 2006, 12:6941-6948.
19. Mamot C., Drummond D.C., Noble C.O., Kallab V., Guo Z., Hong K., et al. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res 2005, 65:11631-11638.
20. Park J.W., Hong K., Kirpotin D.B., Colbern G., Shalaby R., Baselga J., et al. Anti-HER2 immunoliposomes enhanced efficacy attributable to targeted delivery. Clin Cancer Res 2002, 8:1172-1181.
21. Torchilin V.P., Levchenko T.S., Rammohan R., Volodina N., Papahadjopoulos-Sternberg B., D'Souza G.G. Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome-DNA complexes. Proc Natl Acad Sci U S A 2003, 100:1972-1977.
22. Immordino M.L., Dosio F., Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 2006, 1:297-315.
23. Wu S.Y., McMillan N.A. Lipidic systems for in vivo siRNA delivery. AAPS J 2009, 11:639-652.
24. Wilkinson J.M., Grand R.J. Comparison of amino acid sequence of troponin I from different striated muscles. Nature 1978, 271:31-35.
25. Wu A.H. The role of cardiac troponin in the recent redefinition of acute myocardial infarction. Clin Lab Sci 2004, 17:50-52.
26. Meure L.A., Foster N.R., Dehghani F. Conventional and dense gas techniques for the production of liposomes: a review. AAPS PharmSciTech 2008, 9:798-809.
27. Rivest V., Phivilay A., Julien C., Bélanger S., Tremblay C., Emond V., et al. Novel liposomal formulation for targeted gene delivery. Pharm Res 2007, 24:981-990.
28. Khatri K., Goyal A.K., Gupta P.N., Mishra N., Mehta A., Vyas S.P. Surface modified liposomes for nasal delivery of DNA vaccine. Vaccine 2008, 26:2225-2233.
29. Tiwari S., Goyal A.K., Mishra N., Khatri K., Vaidya B., Mehta A., et al. Development and characterization of novel carrier gel core liposomes based transmission blocking malaria vaccine. J Control Release 2009, 140:157-165.
30. Chen C.-W., Lu D.-W., Yeh M.-K., Shiau C.-Y., Chiang C.-H. Novel RGD-lipid conjugate-modified liposomes for enhancing siRNA delivery in human retinal pigment epithelial cells. Int J Nanomedicine 2011, 6:2567.
31. Gao D., Tang S., Tong Q. Oleanolic acid liposomes with polyethylene glycol modification: promising antitumor drug delivery. Int J Nanomedicine 2012, 7:3517-3526.
32. Chu M.-J., Wang Y.-Z., Itagaki K., Ma H.-X., Xin P., Zhou X.-G., et al. Identification of active compounds from Caesalpinia sappan L. extracts suppressing IL-6 production in RAW 264.7 cells by PLS. J Ethnopharmacol 2013, 148:37-44.
33. Shao M., Sun S-l, Li M-h, Li B-x, Yu H., Shen Z-y, et al. The liposomal daunorubicin plus tamoxifen: improving the stability, uptake, and biodistribution of carriers. J Liposome Res 2012, 22:168-176.
34. Hao Z.F., Cui Y.X., Li M.H., Du D., Liu M.F., Tao H.Q., et al. Liposomes modified with P-aminophenyl-alpha-d-mannopyranoside: a carrier for targeting cerebral functional regions in mice. Eur J Pharm Biopharm 2013, 84:505-516.
35. + currents densities in ventricular myocytes of guinea pigs by chronic oxidant stress. Acta Pharmacol Sin 2004, 25:751-755.
36. Shan H., Li X., Pan Z., Zhang L., Cai B., Zhang Y., et al. Tanshinone IIA protects against sudden cardiac death induced by lethal arrhythmias via repression of microRNA-1. Br J Pharmacol 2009, 158:1227-1235.
37. Li B.-X., Yang B.-F., Zhou J., Xu C., Li Y.-R. Inhibitory effects of berberine on IK1, IK, and HERG channels of cardiac myocytes. Acta Pharmacol Sin 2001, 22:125.
38. Li H., Xie Y.H., Yang Q., Wang S.W., Zhang B.L., Wang J.B., et al. Cardioprotective effect of paeonol and danshensu combination on isoproterenol-induced myocardial injury in rats. PLoS One 2012, 7:e48872.
39. Han H.D., Lee A., Song C.K., Hwang T., Seong H., Lee C.O., et al. In vivo distribution and antitumor activity of heparin-stabilized doxorubicin-loaded liposomes. Int J Pharm 2006, 313:181-188.
40. Latronico M.V., Catalucci D., Condorelli G. Emerging role of microRNAs in cardiovascular biology. Circ Res 2007, 101:1225-1236.
41. Zhao Y., Ransom J.F., Li A., Vedantham V., von Drehle M., Muth A.N., et al. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell. 2007, 129:303-317.
42. Li S.-D., Huang L. Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting. J Control Release 2010, 145:178.
43. Doi K., Oku N., Toyota T., Shuto S., Sakai A., Itoh H., et al. Therapeutic effect of reticuloendothelial system (RES)-avoiding liposomes containing a phospholipid analogue of 5-fluorouracil, dipalmitoylphosphatidylfluorouridine, in Meth A sarcoma-bearing mice. Biol Pharml Bull 1994, 17:1414-1416.
44. Ntziachristos V., Bremer C., Weissleder R. Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging. Eur radiol 2003, 13:195-208.